Fenwick & West LLP represented Bothell, WA-based LipoSonix, Inc. in its recently announced acquisition by Medicis (NYSE: MRX), a specialty pharmaceutical company focusing primarily on the treatment of dermatological and aesthetic conditions. LipoSonix has developed a non-invasive ultrasound technology designed to treat troublesome areas of fat that may not respond well to diet or exercise.
Under the terms of the transaction, Medicis will pay $150 million in cash for all of the outstanding shares of privately-held LipoSonix. In addition, Medicis will pay LipoSonix stockholders certain milestone payments up to an additional $150 million upon FDA approval of the LipoSonix technology and if various commercial milestones are achieved on a worldwide basis.
The Fenwick & West transaction team included corporate attorneys Stephen Graham, David Michaels, Matt Forkner, Kristin O'Hanlon, Theresa Shaw and Andrew Albertson; licensing attorney Roger Tolbert; executive compensation and employee benefits attorneys Blake Martell and Nicholas Frey; and tax attorney Ron Schrotenboer; and corporate paralegal Ellen Welichko.
Fenwick & West provides comprehensive legal services to technology and life sciences clients of national and international prominence. The firm is ranked by MergerMarket as one of the top 5 technology M&A practices in the U.S. and by Mergerstat as one of the top 15 U.S. law firms for life sciences M&A.